Prosecution Insights
Last updated: April 18, 2026
Application No. 17/635,658

METHODS AND SYSTEMS FOR CELL CULTURE

Final Rejection §103
Filed
Sep 06, 2022
Examiner
BERKE-SCHLESSEL, DAVID W
Art Unit
1651
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Instituto Tecnológico Y De Estudios Superiores De Monterrey
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allow Rate
484 granted / 731 resolved
+6.2% vs TC avg
Strong +32% interview lift
Without
With
+32.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
40 currently pending
Career history
771
Total Applications
across all art units

Statute-Specific Performance

§101
8.1%
-31.9% vs TC avg
§103
34.4%
-5.6% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 731 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments The Applicant has provided amendments to the claims, and arguments in response to the previous Office Action. The provided drawings have allowed for a withdrawal of the objection to the drawings. Additionally, all of the “such as” language has been removed, and as such, these 35 USC 112(b) rejections are withdrawn. Finally, the dependency of claim 26 has been corrected, and the previous 35 USC 112(b) rejection is withdrawn. On page 8 of the Applicant’s Arguments, the Applicant states that the ordinary artisan would not have a reasonable expectation of success when applying one cell printing methodology to another cell printing system. The Applicant has provided no explicit reason or evidence for this, and has provided no clear rationale as to why the Examiner’s assertions are improper. The Applicant continues by stating that the Office has not demonstrated that the combination would predictably result in a perfusable scaffold of claim 1. The Office does not have laboratories to test the viability of the Applicant’s assertions or the predictability of hypothetical combinations. If the Applicant can provide reasonable evidence to suggest that the cited combination would not be predictable, this could be used as evidence of non-obviousness; however, barring evidence, the combination continues to be obvious and predictable. See MPEP 2145(I). On page 8 of the Applicant’s Arguments, the Applicant asserts that the prior art teaches away from the combination. As neither reference explicitly or implicitly states that these methods would be incompatible, there is no evidence that the prior art teaches away from the combination. See MPEP 2143.01(I). No claim is allowed. All 35 USC 103 rejections are maintained. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-10, 12, 13, 15-17, 19, 20 and 26 is/are rejected under 35 U.S.C. 103 as being unpatentable over Lewis, et al (PGPub 2018/0030409 [IDS Reference]) and Trujillo-de Santiago, et al (Materials Horizons, 5, 813-822, 2018 [IDS Reference]) and evidenced by Sanchez Rodriguez (Instituto Tecnológico y de Estudios Superiores de Monterrey; Master’s Thesis; May 2019). Lewis teaches a preparation method for a perfusable scaffold for cell culture. See paragraph [0004] [0008]. Lewis provides a fugitive ink composition and an ink composition referred to as a “cell-laden ink.” See paragraph [0168]. Lewis’ “cell-laden ink” is interpreted to be consistent with the claimed “bioink.” Lewis teaches curing of the ink composition, followed by removal of the fugitive ink, wherein a perfusable scaffold is formed. See paragraph [0164] [0168]. Although Lewis does print these inks onto a surface, using a 3D printer, Lewis never explicitly teaches the use of “chaotic printing.” See paragraph [0078]. Trujillo-de Santiago teaches the chaotic printing of bioinks. Trujillo-de Santiago notes that this process provides for the “exponentially fast creation of fine microstructures,” wherein the process provides for improved resolution and speed over current 3D printing techniques. See page 813, “Abstract” section. As such, Trujillo-de Santiago explicitly motivates the ordinary artisan to select chaotic printing over conventional 3D printing techniques, because of the clear advantages. Since Lewis teaches 3D printing techniques, there would be a clear motivation to apply Trujillo-de Santiago’s chaotic printing to the methods of Lewis. Sanchez Rodriguez provides for further motivation by stating the advantages of chaotic printing. See page 63, entire. With respect to claim 1, Lewis teaches all of the claimed elements, except provides for a method that utilizes conventional 3D printing, instead of the claimed chaotic printing. However, Trujillo-de Santiago explicitly motivates the ordinary artisan to apply chaotic printing, since it is clearly stated that chaotic printing is superior to 3D printing. With respect to claim 2, Lewis provides for a “cell-laden ink,” which is interpreted as being consistent with the claimed “bioink.” With respect to claim 3, Lewis generates a perfusable scaffold with a fugitive ink, and 2 bioinks; Trujillo-de Santiago introduces endothelial cells to this scaffold. See paragraph [0168]. With respect to claim 4, throughout Lewis, it is clear that the cells in the bioink fulfill the claimed cell-types. See paragraph [0008]. With respect to claims 5 and 6, both Trujillo-de Santiago and Sanchez Rodriguez indicate that chaotic printing provides for laminar flow and mixing. See Trujillo-de Santiago, page 813, “Conceptual insights” section; page 814, “Using chaos to fabricate fine microstructures” section, 1st paragraph; see Sanchez Rodrigues, page 63, entire. Additinally, Lewis provides methods to suggest that the fugitive ink and the “cell-laden ink” (interpreted as bioink) are premixed prior to printing. See paragraph [0189] [0203] [0205] [0216] [0217]. With respect to claim 7, Trujillo-de Santiago suggests that the claimed mixing would be obvious to the ordinary artisan. See page 814, “Using chaos to fabricate fine microstructures” section; page 815, Figure 2. With respect to claim 8, Trujillo-de Santiago teaches that striation thickness can be tuned, but explicitly teaches 5-20 µm. See page 818, left column, 1st [full] paragraph. With respect to claims 9 and 10, although Trujillo-de Santiago does not state the surface area-to-volume ratio or surface density, Trujillo-de Santiago notes the high degree of tunability of the process. See page 813, “Abstract” section; page 820, “Conclusions” section. As such, it would be reasonable to suggest that the ordinary artisan would be wholly capable of tuning the surface area-to-volume ratio, and surface density, in a manner that is ideal for any particular method. With respect to claim 12, Lewis teaches 3D printing. See paragraph [0004]. Lewis indicates that 3D printing involved extrusion from a nozzle. See paragraph [0155]. Trujillo-de Santiago confirms that 3D printing relies on extrusion, and further indicates that chaotic printing relies on extrusion. See page 814, “Introduction” section; page 816, right column, last paragraph. With respect to claim 13, Trujillo-de Santiago indicates that the bioink includes gelatin methacryloyl. See page 815, left column, 1st [incomplete] paragraph; page 819, left column, 1st [incomplete] paragraph. With respect to claims 15-17, Lewis teaches polysaccharides, proteins, and synthetic polymers. See paragraph [0122]. With respect to claim 19, although not explicitly stated in the prior art, the ordinary artisan would be well-versed and highly accustom to the optimization of 3D printing ink consistency. As such, it would be obvious to the ordinary artisan to optimize the flow/viscosity of the bioink. With respect to claim 20, Trujillo-de Santiago indicates that the bioink can be functionalized with a growth factor. See page 819, left column, 1st [incomplete] paragraph. With respect to claim 26, Trujilo-de Santiago teaches polymers in the claimed amounts. See page 813. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID W BERKE-SCHLESSEL whose telephone number is (571)270-3643. The examiner can normally be reached M-F 8AM-5:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAVID W BERKE-SCHLESSEL/Primary Examiner, Art Unit 1651
Read full office action

Prosecution Timeline

Sep 06, 2022
Application Filed
Sep 12, 2025
Non-Final Rejection — §103
Mar 16, 2026
Response Filed
Apr 07, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599634
Nerve Guidance Conduit Comprising Neural Crest Stem-Like Cells and/or Schwann Cell Precursor-Like Cells and Methods of Making and Using the Same
2y 5m to grant Granted Apr 14, 2026
Patent 12576076
USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY
2y 5m to grant Granted Mar 17, 2026
Patent 12571791
METHODS FOR EVALUATING CARDIAC SAFETY OF DRUG USING CARDIOMYOCYTES DERIVED FROM HUMAN STEM CELLS
2y 5m to grant Granted Mar 10, 2026
Patent 12569806
DEVICES, METHODS, AND SYSTEMS FOR CAPTURING AND SEQUESTERING ATMOSPHERIC GASES
2y 5m to grant Granted Mar 10, 2026
Patent 12560592
STABLY-INVERTED ORGANOIDS AND METHODS OF PRODUCING AND USING THE SAME
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+32.5%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 731 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month